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Because incidence and immunohistochemical features of pulmonary pleomorphic carcinoma (PC) are
unclear, the author retrospectively surveyed and re-examined the archival 718 lung malignancy samples
in our laboratory. As the results, one case of pulmonary PC was found; thus the incidence of pulmonary
PC was 0.14% of all lung malignancies. A 67-year-old woman with asthma was found to have a rapidly
growing tumor in the peripheral lower lobe of right lung at a private clinic, and was referred to our
hospital. She was a non-smoker. Imaging modalities showed a cystic tumor, and clinical diagnosis was
bronchogenic cyst. Right lower lobectomy was performed. The patient is now alive without tumors six
years after the operation. Grossly, the tumor was well-deﬁned white tumor with necrosis. The tumor
measured 5 4 5 cm. Histologically, the tumor was pulmonary PC consisting of malignant spindle and
giant cells with focal tubular formations. Necrotic foci and numerous mitotic ﬁgures were present.
Immunohistochemically, tumor cells were positive for pancytokeratin, high molecular weight cytoker-
atin (CK), CK5/6, CK7, CK14, CK18, CK19, epithelial membrane antigen, vimentin, p53 protein, surfactant
apoprotein A, neuron-speciﬁc enolase, lysozyme, Ki-67 (60%), and CD68. Tumor cells were negative for
CK20, thyroid transcriptional factor-1, CEA, S100 protein, desmin, a-smooth muscle actin, melanosome,
CD34, p63, chromogranin, synaptophysin, CD56, KIT, and platelet-derived growth factor-a. It appeared
that the present pulmonary PC is associated with adenocarcinoma or derived from sarcomatous trans-
formation of adenocarcinoma.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Sarcomatoid carcinoma of the lung is rare, and its incidence is
estimated to be 0.3–1.3% of all lung malignancies.1–5 According to
WHO classiﬁcation,5 sarcomatoid carcinoma of the lung is deﬁned
as a group of poorly differentiated non-small cell lung carcinoma
that shows sarcoma or sarcoma-like (spindle and/or giant cell)
differentiation. Sarcomatoid carcinoma is classiﬁed into the
following ﬁve histological variants: pleomorphic carcinoma (PC),
spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and
pulmonary blastoma.5 PC is deﬁned as a poorly differentiated non-
small cell carcinoma, namely squamous cell carcinoma, adenocar-
cinoma or large cell carcinoma containing spindle cells and/or giant
cells or, a carcinoma consisting only of spindle and giant cells.5
Although sarcomatoid carcinoma of the lung has been investigated
in several reports,1–8 there are no comprehensive reports on PC of
the lung, to the best of the author’s knowledge. However, recentlyrved.a study of PC using large series was published.8 In addition, the
incidence and immunohistochemical features of PC are unknown.
Therefore, the author investigated PC of the lung in the archival ﬁle
of our laboratory.2. Materials and methods
The author retrospectively surveyed and re-examined 718 cases
of lung cancer (biopsy, 586 cases; surgical, 132 cases) in our labo-
ratory, and selected PC. The clinical records of the selected PC of the
lung were reviewed. An immunohistochemical study was per-
formed by Dako envision method (Dako Corp., Glostrup, Denmark)
as previously described.9,10 The antigens examined are shown in
Table 1.3. Results
3.1. Incidence
One case of PC was found out of the 718 cases. Therefore, the
incidence of PC of the lung was 0.14% of all lung malignancies.
Table 1
Immunohistochemical reagents and results.
Antigens Antibodies (clone) Sources Results
Pancytokeratin AE1/3 Dako Corp. Glostrup, Denmark þþþ
Pancytokeratin Polyclonal wide Dako þþþ
Pancytokeratin KL-1 Immunotech, Marseille, France þþ
HMWCK 34bE12 Dako þ
CK5/6 D5/16 Dako þ
CK7 N1626 Dako þ
CK14 LL002 Novocastra, Newcastle upon
type, UK
þ
CK18 DC10 Dako þþþ
CK19 RCK 108 Progen, Heidelberg, Germany þþ
CK20 K20.8 Dako –
EMA E29 Dako þ
Vimentin Vim 3B4 Dako þþ
TTF-1 8G7G3/1 Dako 
CEA Polyclonal Dako 
Desmin D33 Dako 
S100 protein Polyclonal Dako 
Melanosome HMB45 Dako 
ASMA 1A4 Dako 
CD34 NU-4A1 Nichirei, Tokyo, Japan 
p53 protein DO-7 Dako þþþ
p63 4A4 Dako 
SP-A PE-10 Dako þ
Ki-67 MIB-I Dako 60%
Chromogranin DAK-A3 Dako 
Synaptophysin Polyclonal Dako 
NSE BBS/NC/VI-H14 Dako þ
CD56 UJ13A Dako 
Lysozyme Polyclonal Dako þ
CD68 KP-1 Dako þ
KIT Polyclonal Dako 
Fig. 1. Gross features of the tumor. The tumor is well deﬁned and white. Necrotic foci
are present. The tumor measures 5 5 4 cm.
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A 67-year-old woman with asthma was found to have a rapidly
growing tumor in the peripheral lower lobe of right lung at
a private clinic, and was referred to our hospital. She was non-
smoker. Imaging modalities showed a cystic tumor, and clinical
diagnosis was bronchogenic cyst. Right lower lobectomy was per-
formed. The patient is now alive without tumors six years after the
operation.PDGFRA Polyclonal Santa Cruz, CA, USA 
þþþ, 67–100% positive; þþ, 33–66% positive; þ, 1–33% positive; , negative.
HMWCK, high molecular weight cytokeratin; CK, cytokeratin; TTF-1, thyroid tran-
scriptional factor-1; EMA, epithelial membrane antigen; CEA, carcinoembryonic
antigen; ASMA, a-smooth muscle antigen; SP-A, surfactant apoprotein A; NSE,
neuron-speciﬁc enolase; PDGFRA, platelet-derived growth factor receptot-a.3.3. Morphologies and immunohistochemistry
Grossly, the tumor was well-deﬁned white one with necrosis
(Fig. 1). It measured 5 5 4 cm. Histologically, the tumor wasFig. 2. (A) Low power view of the tumor. The tumor consists of malignant spindle cells, polygonal cells and giant cells. Necrotic areas are scattered. HE, 20. (B) Malignant tubular
formations are seen. HE, 200. (C) Malignant spindle cells are seen. HE, 200. (D) Malignant giant cells are seen. HE, 200.
Fig. 3. (A) Cytokeratin AE1/3 is positive. Immunostaining, 100. (B) Cytokeratin 5/6 is positive. Immunostaining, 100. (C) Vimentin is positive. Immunostaining, 100. (D) p53
protein is positive. Immunostaining, 100. (E) Surfactant apoprotein A is positive in some tumor cells. Immunostaining, 200. (F) Ki-67 labeling is 60%. Immunostaining, 100. (G)
CD68 is positive in some tumor cells, Immunostaining, 200.
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(Fig. 2A–D). Necrotic areas were scattered (Fig. 2A). Glandular
structures of tumor cells were recognized in a few places (Fig. 2B).
The malignant spindle cells and polygonal cells showed decreased
cohesiveness (Fig. 2C). The giant cells were malignant cells
(Fig. 2D). There were numerous mitotic ﬁgures. Inﬂammatory cells
were also seen particularly around the necrotic areas.
Immunohistochimical results are shown in Table 1. Immuno-
histochemically, tumor cells were positive for pancytokeratin
(Fig. 3A), high molecular weight cytokeratin (CK), CK5/6 (Fig. 3B),
CK7, CK14, CK18, CK19, epithelial membrane antigen, vimentin
(Fig. 3C), p53 protein (Fig. 3D), surfactant apoprotein A (SP-A)
(Fig. 3E), neuron-speciﬁc enolase, Ki-67 (60%) (Fig. 3F), lysozyme,
and CD68 (Fig. 3G). In contrast, tumor cells were negative for CK20,
thyroid transcriptional factor-1 (TTF-1), CEA, S100 protein, desmin,
a-smooth muscle actin, melanosome, CD34, p63, chromogranin,
synaptophysin, CD56, KIT, and platelet-derived growth factor-a.
4. Discussion
The present case consisted of malignant spindle cells, polygonal
cells, giant cells, and tumor tubules. The immunohistochemical
study showed positive reactions for cytokeratins and vimentin, and
negative reactions for mesenchymal markers such as S100 protein,
indicating that the present tumor is not sarcoma but a carcinoma.
The histological and immunohistochemical ﬁndings of the present
case fulﬁll the criteria of PC of WHO.5
Clinically, most patients with PC show relatively aggressive
course, and were smokers.1–8 Male to female ratio is about 5:1. The
initial symptoms are those of respiratory symptoms such as
hemoptysis and cough. In contrast, the present case was a female
and non-smoker. The tumor was ﬁrst detected by routine X-ray
examination, and clinically was diagnosed as bronchogenic cyst.
Further, the present case is nowalive six years after operation. Thus,
the present PC case did not show typical clinical features of PC.
The incidence of PC of the lung has been unclear. The incidence
of sarcomatoid carcinoma of the lung was estimated to be 0.3–
1.3%.5 In the present study, the incidence of PC was 0.14%, sug-
gesting that PC of the lung is a very rare neoplasm.
Immunohistochemical study plays an important role in deter-
mining histological type of non-small lung carcinoma.11–16 In
general, CK5/6 and p63 are markers of squamous cell carcinoma
17,18. SP-A and TTF-1 are markers of adenocarcinoma 19,20. CK7 and
CK20 are important in discriminating primary lung carcinoma and
metastatic lung carcinoma. The present case was positive for SP-A,
CK5/6 and CK7, but negative for TTF-1, p63 and CK20. The CD7/
CK20 pattern is consistent with primary lung carcinoma in the
present case. Other antigens are non-contributory.
Immunohistochemical studies of PC have been rarely investi-
gated. The present study employed relatively extensive immuno-
histochemical studies. Histologically, the present case showed
adenocarcinomaelements and immunohistochemicallywaspositive
for SP-A. SP-A is a speciﬁc marker of lung adenocarcinoma 20. These
histological and immunohistochemical ﬁndings strongly suggest an
adenocarcinoma nature of the present study. It seems possible that
the present PC case may be derived from adenocarcinoma. Mochi-
zuki et al.,8 who reported clinicopathologic features of 70 cases of PC,
described that PC was classiﬁed into three groups, i.e. adenocarci-
noma group, squamous cell carcinoma group, and large cell carci-
noma group. The present case belongs to adenocarcinoma group.
Cytokeratin proﬁling of PC of the lung has not been studied.
Addis and Corrin6 reported that pancytokeratin (CAM 5.2 and LP
34) was present in sarcomatoid carcinoma of the lung. The present
study revealed board expression of various CKs; only CK20 was
negative. These observations suggest that PC may have various CKs.P53 protein was expressed in the present study; the expression
was broad. P53 expression in sarcomatoid carcinoma of the lung has
been reported only once by Holst et al.21 They found p53 expression
in 4 cases out of 9 cases of spindle cell carcinoma of the lung. The
present observations support the malignant nature of the present
tumor. More studies are required for p53 protein expression.
Ki-67 has not been reported in PC. The present cases showed
a 60% labeling index, indicating high proliferative fraction in PC of
the lung. This also supports the malignant characters of the present
tumor.
Neuroendocrine carcinoma frequently occurs in the lung, such as
small cell lung carcinoma and large cell neuroendocrine carcinoma.
In the present case, neuroendocrine markers (chromogranin, syn-
aptophysin, and CD56) were negative, suggesting that the present
tumors are not associated with neuroendocrine differentiation.
It was strange that the present case showed lysozyme and CD68
immunoreactivity in some tumor cells. This is an enigma. It may be
possible that the present PC shows histiocytic differentiation.
However, this is not reasonable. Much more immunohistochemical
studies are needed.
There have been no reports of CD56, KIT and platelet-derived
growth factor-a in PC of the lung. The present case was negative for
CD56, KIT, and platelet-derived growth factor-a, suggesting the
present tumors were not associated with histiocytic tumors and
KIT-positive tumors such as neuroendocrine carcinomas and
extragastrointestinal stromal tumors.
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